Cambridge Cognition CEO on growth, pharma & CANTAB Pathway solution

Cambridge Cognition Holdings PLC (AIM:COG) CEO Rob Baker talked with Proactive's Stephen Gunnion about the company’s neuroscience technology platform, its strong commercial momentum, and how validated cognitive assessments are being expanded beyond clinical trials into real-world and at-home use. Baker explained that Cambridge Cognition is focused on brain health, developing scientifically validated digital and voice-based cognitive assessments that objectively measure cognition. He outlined how the company’s tools are used by researchers to drive scientific discovery, by pharmaceutical companies to support patient identification and drug development in the central nervous system space, and by clinicians to improve patient care through ongoing monitoring. Discussing the company’s trading update for the year to 31 December, 2025, Baker highlighted a sharp increase in new sales orders, driven by a renewed commercial focus on large pharmaceutical customers. He said the team placed greater emphasis on communicating the scientific validation and value proposition of its tools, ensuring they could meet the growing challenges faced by drug developers. As Baker put it, the strategy was about “relentlessly focus[ing] on that commercial strategy” and execution. A key solution discussed was CANTAB Pathways, which builds on decades of validated assessments with thousands of scientific publications behind them. Baker explained that the solution is designed to move from rapid cognitive screening through to deeper, multi-domain assessment and ongoing monitoring, addressing a clear gap in real-world cognitive measurement. Looking ahead, Baker outlined the opportunity to bring brain health measurement into the home, likening it to how blood pressure monitoring has moved beyond the clinic. He also pointed to progress in consumer health and wellness partnerships and said investors should watch continued execution, revenue growth and expansion into healthcare and consumer applications during 2026. For more interviews like this, visit Proactive’s YouTube channel, give the video a like, subscribe to the channel, and enable notifications so you don’t miss future updates. #CambridgeCognition #BrainHealth #CognitiveAssessment #DigitalHealth #Neuroscience #CANTAB #HealthcareTechnology #PharmaInnovation #ClinicalTrials #InvestorInterview #ProactiveInvestors